The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis
Open accessAbstract
BACKGROUND Transthyretin amyloidosis (ATTR) is a heterogeneous disorder with multiorgan involvement and a genetic or nongenetic basis. OBJECTIVES We described ATTR in the United States in the THAOS (Transthyretin Amyloidosis Outcomes Survey) registry. METHODS Demographic, clinical, and genetic features of patients enrolled in the THAOS registry in the United States (n = 390) were compared to other regions of the world (ROW) (n = 2,140) with a focus on the phenotypic expression and survival in the majority of U.S. subjects with Val122Ile (n = 91) and wild-type ATTR (n = 189). RESULTS U.S. subjects are older (70 vs. 46 years), more often male (85.4% vs. 50.6%) and more often of African descent (25.4% vs. 0.5%) than ROW. A significantly higher percentage of U.S. patients with ATTR amyloid seen at cardiology sites had wild-type disease than the ROW (50.5% vs. 26.2%). In the United States, 34 different mutations (n = 201) have been reported, with the most common being Val122Ile (n = 91; 45.3%) and Thr60Ala (n = 41; 20.4%). Overall, 91 of 107 patients with Val122Ile (85%) were from the United States, where Val122Ile subjects were younger and more often women and black than wild-type patients, and had similar cardiac phenotype but a greater burden of neurologic symptoms (pain, numbness, tingling, and walking disability) and worse quality of life. Advancing age and lower mean arterial pressure, but not the presence of a TTR mutation, were independently associated with higher mortality from a multivariate analysis of survival. CONCLUSIONS In the THAOS registry, ATTR in the United States is overwhelmingly a disorder of older adult males with a cardiac-predominant phenotype. Val122Ile is the most common TTR mutation, and neurologic phenotypic expression differs between wild-type disease and Val122Ile, but survival from enrollment in THAOS does not. CLINICAL TRIAL NCT00628745
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J. S., et al. (2005) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2005.10.005 · Cited by 11,318
Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings
Devereux, R. B., Alonso, D. R., Lutas, E. M., Gottlieb, G. J., Campo, E., Sachs, I., & Reichek, N. (1986) · The American Journal of Cardiology · doi:10.1016/0002-9149(86)90771-x · Cited by 6,229
The clinical evaluation of chemotherapeutic agents in cancer
Karnofsky, D. A. (1949) · Medical Entomology and Zoology · Cited by 2,933
Falk, R. H., Comenzo, R. L., & Skinner, M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709253371306 · Cited by 1,180
Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction
González-López, E., Gallego-Delgado, M., Guzzo-Merello, G., de Haro-del Moral, F. J., Cobo-Marcos, M., Robles, C., Bornstein, B., Salas, C., Lara-Pezzi, E., Alonso-Pulpon, L., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv338 · Cited by 1,174
Evaluation of chemotherapeutic agents
A.R.L. (1950) · The American Journal of Medicine · doi:10.1016/0002-9343(50)90056-8 · Cited by 1,004
Perugini, E., Guidalotti, P. L., Salvi, F., Cooke, R. M. T., Pettinato, C., Riva, L., Leone, O., Farsad, M., Ciliberti, P., Bacchi-Reggiani, L., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.073 · Cited by 981
Self-citationSafety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Self-citationTafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial
Coelho, T., Maia, L. F., Martins da Silva, A., Waddington Cruz, M., Planté-Bordeneuve, V., Lozeron, P., Suhr, O. B., Campistol, J. M., Conceição, I. M., Schmidt, H. H.-J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182661eb1 · Cited by 816
Self-citationBokhari, S., Castaño, A., Pozniakoff, T., Deslisle, S., Latif, F., & Maurer, M. S. (2013) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.112.000132 · Cited by 622
Self-citation
Cited by
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Self-citationTafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Self-citation2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Self-citationTransthyretin Amyloid Cardiomyopathy
Ruberg, F. L., Grogan, M., Hanna, M., Kelly, J. W., & Maurer, M. S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.04.003 · Cited by 1,112
Self-citation2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.011 · Cited by 931
Self-citationKittleson, M. M., Maurer, M. S., Ambardekar, A. V., Bullock-Palmer, R. P., Chang, P. P., Eisen, H. J., Nair, A. P., Nativi-Nicolau, J., Ruberg, F. L., & On behalf of the American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology (2020) · Circulation · doi:10.1161/cir.0000000000000792 · Cited by 756
Self-citationKittleson, M. M., Ruberg, F. L., Ambardekar, A. V., Brannagan, T. H., Cheng, R. K., Clarke, J. O., Dember, L. M., Frantz, J. G., Hershberger, R. E., Maurer, M. S., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.11.022 · Cited by 640
Self-citationAddressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis
Maurer, M. S., Elliott, P., Comenzo, R., Semigran, M., & Rapezzi, C. (2017) · Circulation · doi:10.1161/circulationaha.116.024438 · Cited by 492
Self-citationVutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
Fontana, M., Berk, J. L., Gillmore, J. D., Witteles, R. M., Grogan, M., Drachman, B., Damy, T., Garcia-Pavia, P., Taubel, J., Solomon, S. D., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2409134 · Cited by 462
Self-citationHereditary transthyretin amyloidosis: a model of medical progress for a fatal disease
Adams, D., Koike, H., Slama, M., & Coelho, T. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0210-4 · Cited by 448
Self-citationHeidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001062 · Cited by 394
Self-citationScreening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice
Witteles, R. M., Bokhari, S., Damy, T., Elliott, P. M., Falk, R. H., Fine, N. M., Gospodinova, M., Obici, L., Rapezzi, C., & Garcia-Pavia, P. (2019) · JACC: Heart Failure · doi:10.1016/j.jchf.2019.04.010 · Cited by 351
Self-citationPatisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis
Maurer, M. S., Kale, P., Fontana, M., Berk, J. L., Grogan, M., Gustafsson, F., Hung, R. R., Gottlieb, R. L., Damy, T., González-Duarte, A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2300757 · Cited by 339
Self-citationSystemic amyloidosis from A (AA) to T (ATTR): a review
Muchtar, E., Dispenzieri, A., Magen, H., Grogan, M., Mauermann, M., McPhail, E. D., Kurtin, P. J., Leung, N., Buadi, F. K., Dingli, D., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13169 · Cited by 327
Self-citationThe Pathology of Amyloidosis in Classification: A Review
Picken, M. M. (2020) · Acta Haematologica · doi:10.1159/000506696 · Cited by 313
Aortic Stenosis and Cardiac Amyloidosis
Ternacle, J., Krapf, L., Mohty, D., Magne, J., Nguyen, A., Galat, A., Gallet, R., Teiger, E., Côté, N., Clavel, M.-A., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.09.056 · Cited by 294
Self-citationThe Dual-Tree Complex Wavelet Transform: A New Efficient Tool For Image Restoration And Enhancement
Kingsbury, N. (1998) · doi:10.5281/zenodo.36900 · Cited by 272
Patisiran, an RNAi Therapeutic for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis
Kristen, A. V., Ajroud-Driss, S., Conceição, I., Gorevic, P., Kyriakides, T., & Obici, L. (2019) · Neurodegenerative Disease Management · doi:10.2217/nmt-2018-0033 · Cited by 268
Self-citationGilstrap, L. G., Dominici, F., Wang, Y., El-Sady, M. S., Singh, A., Di Carli, M. F., Falk, R. H., & Dorbala, S. (2019) · Circulation: Heart Failure · doi:10.1161/circheartfailure.118.005407 · Cited by 260
Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction
AbouEzzeddine, O. F., Davies, D. R., Scott, C. G., Fayyaz, A. U., Askew, J. W., McKie, P. M., Noseworthy, P. A., Johnson, G. B., Dunlay, S. M., Borlaug, B. A., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.3070 · Cited by 220
Self-citationAdvances in the treatment of hereditary transthyretin amyloidosis: a review
Gertz, M. A., Mauermann, M. L., Grogan, M., & Coelho, T. (2019) · Brain and Behavior · doi:10.1002/brb3.1371 · Cited by 102
Self-citationRozenbaum, M. H., Large, S., Bhambri, R., Stewart, M., Young, R., Doornewaard, A. V., Dasgupta, N., Masri, A., & Nativi-Nicolau, J. (2021) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2021-0071 · Cited by 19
Metadata
- Authors
- Maurer, M. S., Hanna, M., Grogan, M., Dispenzieri, A., Witteles, R., Drachman, B., Judge, D. P., Lenihan, D. J., Gottlieb, S. S., Shah, S. J., Steidley, D. E., Ventura, H., Murali, S., Silver, M. A., Jacoby, D., Fedson, S., Hummel, S. L., Kristen, A. V., Damy, T., Planté-Bordeneuve, V., Coelho, T., Mundayat, R., Suhr, O. B., Waddington Cruz, M., & Rapezzi, C.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 68
- Issue
- 2
- Pages
- 161-172
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2465483060
- Cited by
- 538
- References
- 34
- FWCI
- 14.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.